$SLRX
Salarius Pharmaceuticals, Inc.

2020 Q1 Form 10-K Financial Statement

#000161521920000014 Filed on March 23, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 2018 Q4
Revenue $1.133M $3.465M $163.1K
YoY Change 979.12% 77.57% -42.34%
Cost Of Revenue $74.93K
YoY Change -43.8%
Gross Profit $88.13K
YoY Change -41.04%
Gross Profit Margin 54.05%
Selling, General & Admin $1.860M $7.710M $1.820M
YoY Change 24.83% -24.26% -54.27%
% of Gross Profit 2065.06%
Research & Development $1.643M $4.019M $187.8K
YoY Change 96228.9% 212.12% -95.59%
% of Gross Profit 213.04%
Depreciation & Amortization $4.233K $127.4K $50.00K
YoY Change -88.39% 651.67% -28.57%
% of Gross Profit 56.73%
Operating Expenses $3.502M $11.73M $2.184M
YoY Change 49.13% 222.61% -73.92%
Operating Profit -$2.370M -$8.265M -$2.021M
YoY Change 5.61% 390.62% -75.03%
Interest Expense $2.672K $15.65K $10.00K
YoY Change 4.36% -83.33%
% of Operating Profit
Other Income/Expense, Net $0.00 $20.00K
YoY Change -100.0%
Pretax Income -$2.080M -$6.940M -$2.010M
YoY Change 36.84% -68.34% -74.97%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.084M -$6.936M -$2.009M
YoY Change 36.91% 315.44% -74.98%
Net Earnings / Revenue -183.95% -200.18% -1231.85%
Basic Earnings Per Share
Diluted Earnings Per Share -$218.3K -$2.122M -$2.792M
COMMON SHARES
Basic Shares Outstanding 13.67M shares 18.07M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.600M $3.740M $9.800M
YoY Change 31.51% -61.95% -70.57%
Cash & Equivalents $9.647M $3.740M $3.228M
Short-Term Investments $0.00
Other Short-Term Assets $600.0K $960.0K $22.27K
YoY Change -14.29% 231.03% -97.22%
Inventory $186.9K
Prepaid Expenses
Receivables $600.0K $9.939K
Other Receivables $0.00 $0.00
Total Short-Term Assets $10.90M $4.690M $6.381M
YoY Change 33.8% -54.55% -81.52%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $30.00K $37.53K
YoY Change -100.0% -57.14% -88.66%
Goodwill $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $300.0K $310.0K $195.4K
YoY Change
Total Long-Term Assets $9.200M $9.200M $233.0K
YoY Change 24105.43% 13042.86% -49.1%
TOTAL ASSETS
Total Short-Term Assets $10.90M $4.690M $6.381M
Total Long-Term Assets $9.200M $9.200M $233.0K
Total Assets $20.10M $13.89M $6.614M
YoY Change 145.59% 33.69% -81.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.000M $1.790M $379.8K
YoY Change 436.63% 426.47% -81.05%
Accrued Expenses $800.0K $160.0K $800.0K
YoY Change 14.29% -78.95% -78.38%
Deferred Revenue $4.007M
YoY Change 5450.44%
Short-Term Debt $300.0K $500.0K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.100M $3.310M $1.107M
YoY Change 130.49% 198.2% -81.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.100M $3.310M $1.107M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.100M $3.310M $7.885M
YoY Change 130.49% 198.2% 33.94%
SHAREHOLDERS EQUITY
Retained Earnings -$5.140M
YoY Change -95.37%
Common Stock $203.00
YoY Change -88.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.00M $10.58M -$1.271M
YoY Change
Total Liabilities & Shareholders Equity $20.10M $13.89M $6.614M
YoY Change 145.59% 33.69% -81.1%

Cashflow Statement

Concept 2020 Q1 2019 2018 Q4
OPERATING ACTIVITIES
Net Income -$2.084M -$6.936M -$2.009M
YoY Change 36.91% 315.44% -74.98%
Depreciation, Depletion And Amortization $4.233K $127.4K $50.00K
YoY Change -88.39% 651.67% -28.57%
Cash From Operating Activities -$3.708M -$11.58M -$3.140M
YoY Change 39.47% -377.22% -45.39%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $5.610M $0.00
YoY Change -60.27% -100.0%
Cash From Investing Activities $5.608M $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid $133.6K
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $9.616M $3.579M 0.000
YoY Change 149.38%
NET CHANGE
Cash From Operating Activities -$3.708M -$11.58M -3.140M
Cash From Investing Activities $5.608M 0.000
Cash From Financing Activities $9.616M $3.579M 0.000
Net Change In Cash $5.908M -$2.393M -3.140M
YoY Change -322.21% -142.64% 188.07%
FREE CASH FLOW
Cash From Operating Activities -$3.708M -$11.58M -$3.140M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$11.58M -$3.140M
YoY Change -377.22% -45.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001615219
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019Q2 flks Revenue From Grants Extension Term
RevenueFromGrantsExtensionTerm
P6M
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019 dei Entity File Number
EntityFileNumber
001-36812
CY2019 dei Entity Registrant Name
EntityRegistrantName
SALARIUS PHARMACEUTICALS, INC.
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5087339
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
2450 Holcombe Blvd
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite J 608
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77021
CY2019 dei City Area Code
CityAreaCode
346
CY2019 dei Local Phone Number
LocalPhoneNumber
772-0346
CY2019 dei Security12b Title
Security12bTitle
Common Stock, par value $ 0.0001
CY2019 dei Trading Symbol
TradingSymbol
SLRX
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Entity Public Float
EntityPublicFloat
9203679 USD
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13666453 shares
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3738900 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3228288 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0 USD
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
2903493 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
955899 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
249086 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
4694799 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
6380867 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25016 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37525 USD
CY2019Q4 us-gaap Goodwill
Goodwill
8865909 USD
CY2018Q4 us-gaap Goodwill
Goodwill
0 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
308674 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
195431 USD
CY2019Q4 us-gaap Assets
Assets
13894398 USD
CY2018Q4 us-gaap Assets
Assets
6613823 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1790966 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
379780 USD
CY2019Q4 flks Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
160783 USD
CY2018Q4 flks Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
628990 USD
CY2019Q4 flks Accrued Series A Preferred Units Current
AccruedSeriesAPreferredUnitsCurrent
0 USD
CY2018Q4 flks Accrued Series A Preferred Units Current
AccruedSeriesAPreferredUnitsCurrent
2869412 USD
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
502332 USD
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
541701 USD
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4006755 USD
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
317762 USD
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 USD
CY2019Q4 us-gaap Liabilities
Liabilities
3313544 USD
CY2018Q4 us-gaap Liabilities
Liabilities
7884937 USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4515404 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2338899 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4511174 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2032763 shares
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
451 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
203 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
22657103 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3869120 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12076700 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5140437 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
10580854 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-1271114 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13894398 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6613823 USD
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3465055 USD
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1951351 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4018951 USD
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1287621 USD
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7711181 USD
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2348361 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
11730132 USD
CY2018 us-gaap Operating Expenses
OperatingExpenses
3635982 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-8265077 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-1684631 USD
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1311333 USD
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2019 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
15648 USD
CY2018 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
14994 USD
CY2019 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-6938096 USD
CY2018 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1669637 USD
CY2019 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
1833 USD
CY2018 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-6936263 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-1669637 USD
CY2019 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-6938096 USD
CY2018 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1669637 USD
CY2019 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
CY2018 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
123727 USD
CY2019 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-6938096 USD
CY2018 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-1793364 USD
CY2019 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-2.12
CY2018 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-1.16
CY2019 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0
CY2018 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.12
CY2019 us-gaap Payments Of Dividends
PaymentsOfDividends
133594 USD
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.16
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3268637 shares
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1539388 shares
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-6936263 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-1669637 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
127408 USD
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16950 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
751618 USD
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
30961 USD
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1311333 USD
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-690 USD
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1169 USD
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-91582 USD
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
239540 USD
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-519276 USD
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-285453 USD
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-320637 USD
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3275259 USD
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3465054 USD
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3048649 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11580096 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4177189 USD
CY2019 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
5403634 USD
CY2018 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 USD
CY2019 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
204274 USD
CY2018 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5607908 USD
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2019 flks Proceeds From Redemption Of Equity Securities
ProceedsFromRedemptionOfEquitySecurities
0 USD
CY2018 flks Proceeds From Redemption Of Equity Securities
ProceedsFromRedemptionOfEquitySecurities
25000 USD
CY2019 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
4130786 USD
CY2018 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2025269 USD
CY2018 us-gaap Payments Of Dividends
PaymentsOfDividends
0 USD
CY2019 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
0 USD
CY2018 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
615014 USD
CY2019 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
417885 USD
CY2018 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3579307 USD
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1435255 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2392881 USD
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5612444 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6131781 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
519337 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3738900 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6131781 USD
CY2019 us-gaap Interest Paid Net
InterestPaidNet
9005 USD
CY2018 us-gaap Interest Paid Net
InterestPaidNet
0 USD
CY2019 us-gaap Stock Issued1
StockIssued1
110474 USD
CY2018 us-gaap Stock Issued1
StockIssued1
0 USD
CY2019 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
2869412 USD
CY2018 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
CY2019 flks Prepaid Expense Financed By Note Payable
PrepaidExpenseFinancedByNotePayable
920217 USD
CY2018 flks Prepaid Expense Financed By Note Payable
PrepaidExpenseFinancedByNotePayable
0 USD
CY2019 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 USD
CY2018 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
110474 USD
CY2019Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0 USD
CY2018Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
35713 USD
CY2019 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
CY2018 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1330734 USD
CY2019 flks Accretion Of Dividends
AccretionOfDividends
0 USD
CY2018 flks Accretion Of Dividends
AccretionOfDividends
26999 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-2900426 USD
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
30961 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
123727 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-1669637 USD
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2025269 USD
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1366446 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-1271114 USD
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6932336 USD
CY2019 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
110474 USD
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
751618 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
99758 USD
CY2019 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
11093561 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-6936263 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
10580854 USD
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.</span></div>
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0 USD
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
2903493 USD
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1000000.0 USD
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
4100000 USD
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
110474 USD
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Financial Instruments and Credit RisksFinancial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation (“FDIC”). Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
360234 shares
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39945 shares
CY2019 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Reclassification</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain reclassifications have been made to the prior-year financial statements to conform to the current-year presentation.</span></div>
CY2019Q3 flks Class Of Warrant Or Right Period Warrants Or Rights Unexercisable
ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable
P6M
CY2019 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
3465055 USD
CY2018 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
1951351 USD
CY2019 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-10865500 USD
CY2018 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-21147765 USD
CY2019 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-3.32
CY2018 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-6.47
CY2019Q4 flks Prepaid Clinical Trial Expense
PrepaidClinicalTrialExpense
202743 USD
CY2018Q4 flks Prepaid Clinical Trial Expense
PrepaidClinicalTrialExpense
210333 USD
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
617096 USD
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
16484 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
136060 USD
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
22269 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
955899 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
249086 USD
CY2019Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
900000 USD
CY2019Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0461
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
502332 USD
CY2016Q2 flks Revenue From Grants Maximum Award
RevenueFromGrantsMaximumAward
18700000 USD
CY2016Q2 flks Revenue From Grants Award Term
RevenueFromGrantsAwardTerm
P3Y
CY2019Q4 flks Revenue From Grants Revenue Sharing Payments Continued Payments Percent Of Net Sales
RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales
0.01
CY2019Q4 flks Revenue From Grants Matching Funds Requirement
RevenueFromGrantsMatchingFundsRequirement
0.50
CY2019Q4 flks Revenue From Grants Aggregate Amount Received
RevenueFromGrantsAggregateAmountReceived
9600000 USD
CY2019Q4 flks Revenue From Grants Aggregate Amount Received Current Funding Available
RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable
9100000 USD
CY2019 flks Revenue From Grants Current Funding Received
RevenueFromGrantsCurrentFundingReceived
0 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
541701 USD
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4006755 USD
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
10617 USD
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2869412 USD
CY2018Q4 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
355676 shares
CY2019Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
110474 USD
CY2019Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
142711 shares
CY2019Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2019Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.17
CY2019Q3 flks Class Of Warrant Or Right Threshold Consecutive Trading Days
ClassOfWarrantOrRightThresholdConsecutiveTradingDays
10 trading_Days
CY2019Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y6M
CY2019Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y21D
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
53512 USD
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30961 USD
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
31383 USD
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
90279 shares
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
642360 USD
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0161
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0370
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M14D
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
101082 shares
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.00
CY2019 flks Share Based Compensation Arrangement By Share Based Payment Award Options Options From Business Acquired
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionsFromBusinessAcquired
65151 shares
CY2019 flks Share Based Compensation Arrangements By Share Based Payment Award Options Options From Business Acquired Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOptionsFromBusinessAcquiredWeightedAverageExercisePrice
75.42
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
166233 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
34.42
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M10D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
84321 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
60.09
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y5M12D
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
493360 USD
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y11M19D
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
101082 shares
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1456615 USD
CY2019 flks Effective Income Tax Rate Reconciliation Derivative Fair Value Adjustment Amount
EffectiveIncomeTaxRateReconciliationDerivativeFairValueAdjustmentAmount
-275380 USD
CY2019 flks Effective Income Tax Rate Reconciliation Nondeductible Expense Transaction Costs Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsAmount
232133 USD
CY2019 flks Effective Income Tax Rate Reconciliation Activity Of Acquired Business Amount
EffectiveIncomeTaxRateReconciliationActivityOfAcquiredBusinessAmount
622660 USD
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
23675 USD
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
853527 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
888000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
70000 USD
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
958000 USD
CY2019Q4 flks Deferred Tax Liabilities Deferred Expense Depreciation
DeferredTaxLiabilitiesDeferredExpenseDepreciation
5000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
5000 USD
CY2019Q4 flks Deferred Tax Assets Net Before Valuation Allowance
DeferredTaxAssetsNetBeforeValuationAllowance
953000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
953000 USD
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD

Files In Submission

Name View Source Status
0001615219-20-000014-index-headers.html Edgar Link pending
0001615219-20-000014-index.html Edgar Link pending
0001615219-20-000014.txt Edgar Link pending
0001615219-20-000014-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
flks-20191231.htm Edgar Link pending
flks-20191231.xsd Edgar Link pending
flks-20191231_cal.xml Edgar Link unprocessable
flks-20191231_def.xml Edgar Link unprocessable
flks-20191231_htm.xml Edgar Link completed
flks-20191231_lab.xml Edgar Link unprocessable
flks-20191231_pre.xml Edgar Link unprocessable
image01.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slrx12312019-312exhibi.htm Edgar Link pending
slrx12312019-321exhibi.htm Edgar Link pending
slrx12312019-322exhibi.htm Edgar Link pending
slrx12312019descriptio.htm Edgar Link pending
slrx12312019eyconsent1.htm Edgar Link pending
slrx12312019weavercons.htm Edgar Link pending
slrx20191231-brucemccr.htm Edgar Link pending
slrx20191231ex-311.htm Edgar Link pending
slrx20191231seperation.htm Edgar Link pending